Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cyclerion Therapeutics Inc's Business Segments
Cyclerion Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Option Agreement
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Option Agreement0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Option Agreement | $ 0 | - |
Revenue by Product & Service Category - FY
- Option Agreement100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Option Agreement | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Option Agreement0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Option Agreement | $ 0 | - |
Description of Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for serious and orphan diseases. The company was established in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion is known for its unique approach to drug development, with a primary focus on the soluble guanylate cyclase (sGC) pathway. This pathway plays a crucial role in regulating various physiological processes in the body, including blood flow, inflammation, and fibrosis. By targeting this pathway, Cyclerion aims to develop therapies that could address a wide range of diseases.
The company's pipeline consists of potential treatments for diseases such as sickle cell disease, pulmonary arterial hypertension, and serious cardiometabolic conditions. Cyclerion is also exploring the potential of sGC stimulators in other therapeutic areas, including neurodegenerative disorders.
One of Cyclerion's lead candidates is CY6463, an orally administered sGC stimulator. This drug has shown promise in early clinical trials for its potential to treat a range of diseases associated with impaired nitric oxide signaling. In particular, CY6463 has received attention for its potential to alleviate the painful vaso-occlusive crises associated with sickle cell disease.
Cyclerion's research and development activities are supported by a team of experienced scientists and clinicians who are dedicated to advancing the understanding of sGC biology and its therapeutic potential. The company also collaborates with renowned academic institutions and organizations to leverage their expertise and resources.
In addition to its drug development efforts, Cyclerion is focused on building a sustainable and successful biopharmaceutical company. This includes an emphasis on strong corporate governance, effective financial management, and strategic partnerships.
Overall, Cyclerion Therapeutics Inc. is a cutting-edge biopharmaceutical company that aims to redefine the treatment landscape for serious and orphan diseases through its unique approach to drug development and its focus on the sGC pathway. With a robust pipeline and a dedicated team, Cyclerion strives to provide innovative therapies for patients in need.
Cyclerion is known for its unique approach to drug development, with a primary focus on the soluble guanylate cyclase (sGC) pathway. This pathway plays a crucial role in regulating various physiological processes in the body, including blood flow, inflammation, and fibrosis. By targeting this pathway, Cyclerion aims to develop therapies that could address a wide range of diseases.
The company's pipeline consists of potential treatments for diseases such as sickle cell disease, pulmonary arterial hypertension, and serious cardiometabolic conditions. Cyclerion is also exploring the potential of sGC stimulators in other therapeutic areas, including neurodegenerative disorders.
One of Cyclerion's lead candidates is CY6463, an orally administered sGC stimulator. This drug has shown promise in early clinical trials for its potential to treat a range of diseases associated with impaired nitric oxide signaling. In particular, CY6463 has received attention for its potential to alleviate the painful vaso-occlusive crises associated with sickle cell disease.
Cyclerion's research and development activities are supported by a team of experienced scientists and clinicians who are dedicated to advancing the understanding of sGC biology and its therapeutic potential. The company also collaborates with renowned academic institutions and organizations to leverage their expertise and resources.
In addition to its drug development efforts, Cyclerion is focused on building a sustainable and successful biopharmaceutical company. This includes an emphasis on strong corporate governance, effective financial management, and strategic partnerships.
Overall, Cyclerion Therapeutics Inc. is a cutting-edge biopharmaceutical company that aims to redefine the treatment landscape for serious and orphan diseases through its unique approach to drug development and its focus on the sGC pathway. With a robust pipeline and a dedicated team, Cyclerion strives to provide innovative therapies for patients in need.
Cyclerion Therapeutics Inc. is a biotechnology company primarily focused on developing innovative therapeutics for neurological diseases. Their primary expertise lies in harnessing the potential of the soluble guanylate cyclase (sGC) pathway, which plays a critical role in cellular signaling related to various central nervous system (CNS) disorders. Below is a detailed overview of their segments, products, and services.
Segments
1. Neurological Therapeutics Segment:
- This is the main focus area for Cyclerion, concentrating on drug development for diseases that significantly affect neurological function and mental health. The segment aims to address unmet medical needs in conditions like schizophrenia, Alzheimer’s disease, and chronic pain, among others.
2. Research and Development:
- The R&D segment is dedicated to discovering new therapeutic compounds and advancing clinical trials for existing products. This includes preclinical studies, drug formulation, and testing across various phases of clinical trials (Phase 1, Phase 2, etc.).
3. Collaboration and Partnerships:
- Cyclerion engages in strategic collaborations with other biotech firms, academic institutions, and research organizations. These partnerships aim to leverage expertise, share resources, and co-develop novel treatments.
Products
1. Lead Drug Candidates:
- Cyclerion has developed several promising candidates targeting CNS disorders. These candidates are built around the modulation of the sGC pathway, which is essential for nitric oxide signaling in the brain.
- IC265: A notable candidate aimed at treating conditions such as treatment-resistant depression and other mood disorders. It is designed to enhance cognitive function while also addressing symptoms of mood dysregulation.
- IC145: This candidate targets neuropathic pain and is designed to alleviate chronic pain through a unique mechanism of action involving the sGC pathway. It is currently undergoing clinical evaluation for its efficacy and safety profile.
2. Clinical Trial Programs:
- Cyclerion has established rigorous clinical trial programs for its drug candidates. These trials are designed to evaluate safety, pharmacokinetics, and efficacy in various patient populations.
3. Preclinical Candidates:
- The company also has several preclinical candidate compounds in various stages of development, focusing on different neurological and psychiatric conditions.
Services
1. Research Services:
- Cyclerion provides integrated research services that support both internal and external R&D initiatives. These services include target identification, assay development, and compound screening.
2. Consultation and Advisory:
- The company may offer advisory services leveraging their expertise in CNS disorders to other biotech firms or research organizations looking to develop similar therapeutic pathways. This could include guidance on clinical trial design, regulatory strategy, or market access.
3. Collaborative Development Programs:
- Cyclerion may engage in collaborative programs with partners, enabling shared access to its R&D resources for joint therapeutic developments. These collaborations can maximize the potential of drug candidates through combined innovation and expertise.
4. Regulatory Support:
- Inside its services, Cyclerion may also assist in navigating the complex regulatory pathway necessary for drug approvals, providing insights into compliance with FDA and other international regulatory bodies.
Conclusion
In summary, Cyclerion Therapeutics Inc. is dedicated to advancing innovative therapies aimed at treating significant neurological disorders through the modulation of the sGC pathway. With a rich pipeline of drug candidates under clinical development and a commitment to robust research and collaboration, the company continues to position itself as a key player in the field of CNS therapeutics. Through their various segments, products, and services, Cyclerion remains focused on addressing critical unmet needs in neurobiology and enhancing the quality of life for individuals affected by these challenging conditions.
Segments
1. Neurological Therapeutics Segment:
- This is the main focus area for Cyclerion, concentrating on drug development for diseases that significantly affect neurological function and mental health. The segment aims to address unmet medical needs in conditions like schizophrenia, Alzheimer’s disease, and chronic pain, among others.
2. Research and Development:
- The R&D segment is dedicated to discovering new therapeutic compounds and advancing clinical trials for existing products. This includes preclinical studies, drug formulation, and testing across various phases of clinical trials (Phase 1, Phase 2, etc.).
3. Collaboration and Partnerships:
- Cyclerion engages in strategic collaborations with other biotech firms, academic institutions, and research organizations. These partnerships aim to leverage expertise, share resources, and co-develop novel treatments.
Products
1. Lead Drug Candidates:
- Cyclerion has developed several promising candidates targeting CNS disorders. These candidates are built around the modulation of the sGC pathway, which is essential for nitric oxide signaling in the brain.
- IC265: A notable candidate aimed at treating conditions such as treatment-resistant depression and other mood disorders. It is designed to enhance cognitive function while also addressing symptoms of mood dysregulation.
- IC145: This candidate targets neuropathic pain and is designed to alleviate chronic pain through a unique mechanism of action involving the sGC pathway. It is currently undergoing clinical evaluation for its efficacy and safety profile.
2. Clinical Trial Programs:
- Cyclerion has established rigorous clinical trial programs for its drug candidates. These trials are designed to evaluate safety, pharmacokinetics, and efficacy in various patient populations.
3. Preclinical Candidates:
- The company also has several preclinical candidate compounds in various stages of development, focusing on different neurological and psychiatric conditions.
Services
1. Research Services:
- Cyclerion provides integrated research services that support both internal and external R&D initiatives. These services include target identification, assay development, and compound screening.
2. Consultation and Advisory:
- The company may offer advisory services leveraging their expertise in CNS disorders to other biotech firms or research organizations looking to develop similar therapeutic pathways. This could include guidance on clinical trial design, regulatory strategy, or market access.
3. Collaborative Development Programs:
- Cyclerion may engage in collaborative programs with partners, enabling shared access to its R&D resources for joint therapeutic developments. These collaborations can maximize the potential of drug candidates through combined innovation and expertise.
4. Regulatory Support:
- Inside its services, Cyclerion may also assist in navigating the complex regulatory pathway necessary for drug approvals, providing insights into compliance with FDA and other international regulatory bodies.
Conclusion
In summary, Cyclerion Therapeutics Inc. is dedicated to advancing innovative therapies aimed at treating significant neurological disorders through the modulation of the sGC pathway. With a rich pipeline of drug candidates under clinical development and a commitment to robust research and collaboration, the company continues to position itself as a key player in the field of CNS therapeutics. Through their various segments, products, and services, Cyclerion remains focused on addressing critical unmet needs in neurobiology and enhancing the quality of life for individuals affected by these challenging conditions.